Profound Medical CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Profound Medical Corp. reported a 51% increase in revenue for the year ended December 31, 2025, driven by strong TULSA-PRO sales, but also saw its net loss widen to $42.57 million.
NASDAQ
Profound Medical's 2024 10-K filing reveals a focus on commercializing TULSA-PRO and Sonalleve systems, expanding market reach, and navigating regulatory landscapes.